MIRA today
$0.64-$0.01 (-1.03%)close Nov 13, 2026Trend
DailyUptrend (starting)
4 hourDescending Triangle
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns down below $0.51
Key levels
Resistance$0.79
Resistance$0.71
Support$0.63
Support$0.51
Latest news & SEC filings
LegalDEA issues ruling covering MIRA Pharmaceuticals drug candidates
ProductMIRA Pharmaceuticals reports favorable early SKNY-1 data
ProductMIRA Pharmaceuticals reports SKNY-1 pilot data showing body weight and fat mass reductions
All MIRA news →About MIRA Pharmaceuticals
MIRA Pharmaceuticals is a clinical-stage drug developer working on oral treatments for neurological, psychiatric, metabolic, and addiction-related conditions. Its lead candidate, Ketamir-2, is an NMDA receptor modulator that has finished a Phase 1 trial and is being readied for a Phase 2a study in chemotherapy-induced peripheral neuropathy. Two earlier-stage programs, MIRA-55 for inflammatory pain and SKNY-1 for obesity and nicotine dependence, are in preclinical development. The company holds rights to these candidates in the United States, Canada, and Mexico.
Based on the company's 10-K filed Mar 31, 2026.
Nasdaq · Healthcare
MIRA PHARMACEUTICALS, INC. (MIRA)
What Is the Price Target for MIRA?
SEPT Low Target
$2.98
SEPT Mid Target
$3.50
SEPT High Target
$4.02
Analyst Consensus
$3.50
Is MIRA a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MIRA.
Start Free Trial →Is MIRA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, PEG, Analyst Consensus
Fair Value
$2.48
17
Moat Score
NONE
4/9
Piotroski Score
10.5
Altman Z-Score
What Is Smart Money Doing with MIRA?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MIRA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-164.71%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for MIRA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MIRA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:01:34 | $0.65 | 4,500 | $$3K | BUY |
| 16:21:09 | $0.65 | 1,000 | $$650 | BUY |
| 16:20:46 | $0.65 | 7,440 | $$5K | BUY |
| 16:20:46 | $0.65 | 1,800 | $$1K | BUY |
| 16:20:46 | $0.65 | 1,800 | $$1K | BUY |
5 dark pool trades shown · $$11K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for MIRA PHARMACEUTICALS, INC. (MIRA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MIRA — frequently asked questions
What is MIRA stock price today?
MIRA PHARMACEUTICALS, INC. (MIRA) is at $0.64, down 1.03% (-$0.01) at the Nov 13, 2026 close.
Why is MIRA stock moving today?
Latest MIRA news — Nov 1, 2026: DEA issues ruling covering MIRA Pharmaceuticals drug candidates · Oct 30, 2026: MIRA Pharmaceuticals reports favorable early SKNY-1 data
What is the MIRA price target?
The average analyst price target for MIRA is $3.50, ranging from $4 to $4, based on 1 analysts. Latest: Maxim Group initiates on Sep 17, 2026.
What do analysts rate MIRA?
Analyst ratings for MIRA: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did MIRA beat earnings?
MIRA last reported on Aug 12, 2026: EPS -$0.03.
Does MIRA pay a dividend?
MIRA does not currently pay a dividend.
What are MIRA support and resistance levels?
Support: $0.63, $0.51. Resistance: $0.71, $0.79, $0.85.
What are insiders doing with MIRA?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on MIRA?
Nov 1, 2026: DEA issues ruling covering MIRA Pharmaceuticals drug candidates · Oct 30, 2026: MIRA Pharmaceuticals reports favorable early SKNY-1 data · Oct 29, 2026: MIRA Pharmaceuticals reports SKNY-1 pilot data showing body weight and fat mass reductions